Cannabidiol for acting out dreams

Intervention: It will be administered in patients with Parkinson's disease and REM sleep behavior disorder the drug called canabidiol(CBD) in progressive doses of 75 until 300mg for 12 weeks in 20 patients (group 1) at the same time will be administered the placebo in 20 patients (group 2) during the same time period. The placebo will consist of capsules containing corn oil.;Drug;C10.886.659.633.700;C10.886.659.633;C10.228.140.079.862.500 Primary outcome: 1-A reduction of at least 50% in the frequency of motor symptoms measured by the sleep diary after 12 weeks of intervention. ;A sleep diary will be used to report on the frequency of nocturnal movements. This questionnaire will be completed by the patient or caregivers daily during the baseline period and during the intervention phase that will have 12 consecutive weeks. A reduction of at least 50 percent of the violent nighttime movements is expected in comparison to the baseline period in those who used Canabidiol compared to the placebo group. Secondary outcome: 1-Improvement of the general quality of sleep through Pittsburgh sleep questionnaire; 2-Improvement of the Parkinson's Sleep Scale (PDSS).;The Pittsburgh Sleep Quality Scale will be used to report on subjective sleep quality of patients. The Pittsburgh questionnaire is used worldwide in sleep quality research, it consists of 19 items grouped into 7 major groups that assess duration, latency, sleep efficiency, and daytime complaints. Each group receives a score of 0-3 that is summed to compose a final score or PSQI-Pittsburgh Scale Questionnaire Index, which ranges from 0-21 points. Higher scores indicate poor sleep quality. The choice of such questionnaire was made because it is widely used and easy to apply. With a 5-point cutoff level, it reaches a sensitivity of 89.6% and specificity of 86.5% differentiating healthy individuals from patients with sleep complaints (""good sleeper / bad sleeper""). It will be applied at baseline and after 12 weeks of intervention. An improvement in sleep quality is expected in the cannabidiol group. Patients will also be evaluated through a sleep scale specially developed for PD and called PDSS (Parkinson's Disease Sleep Scale). It is a self-applicable scale consisting of fifteen items, each scoring from zero to four points. The total score ranges from zero (no sleep disturbance) to 60 points. It will be applied at baseline and after 12 weeks of intervention. An improvement in sleep quality in the PDSS group is expected in the cannabidiol group.